Disclaimer: 00Peptides.com is for informational and educational purposes only. It does not provide medical advice. Consult a licensed healthcare professional before considering peptide therapy.
Evidence-grounded information on 29 peptides — dosing protocols, mechanisms of action, and country-specific legal status across 7 jurisdictions. No hype, just the science.
Start with the compounds patients ask about most often.
Long-acting GLP-1 receptor agonist. Increases glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and acts on hypothalamic centres to reduce appetite and food cravings.
Dual GIP and GLP-1 receptor agonist. The added GIP activity appears to enhance insulin sensitivity and amplify weight loss beyond pure GLP-1 agonism.
Synthetic 15-amino-acid fragment derived from a protective protein found in human gastric juice. Promotes angiogenesis through VEGFR2 upregulation, modulates the nitric oxide system, and accelerates fibroblast migration to sites of injury.
Synthetic fragment of the naturally occurring Thymosin Beta-4 protein. Upregulates actin, a structural protein essential for cell migration and proliferation, accelerating wound repair.
GHRH analog. Stimulates the anterior pituitary to release growth hormone in a more natural pulsatile pattern (No-DAC) or with sustained elevation (with DAC).
Selective ghrelin-receptor agonist. Stimulates GH release from the pituitary without significantly elevating cortisol, prolactin, or appetite signals.
Each guide covers the regulator, prescription pathway, and access details.
Health Canada has not authorised most therapeutic peptides as commercial drugs, but compounding pharmacies in Toronto, Vancouver, Calgary, and Montreal dispense many of them on prescription through licensed longevity and sports-medicine clinics. We track the current status of every peptide on this site for Canada.
Long-form coverage of regulation, science, and clinical practice.
CMS expanded Wegovy coverage for cardiovascular indications in 2024, and the 2026 picture for Medicare Part D, Medicaid, and commercial insurers is now clearer. Here is the practical guide.
While 503A compounding has narrowed, 503B outsourcing facilities continue to dispense a small set of peptides. Here is what is available, who qualifies, and how prescribers source it.
Health Canada's framework for therapeutic peptides explained: prescription pathways, compounding pharmacy rules, and the line between approved medicines and research chemicals.
How Australian sports medicine and longevity clinics dispense BPC-157 in 2026 — TGA Schedule 4 compliance, typical pricing, monitoring, and the WADA athlete consideration.